XML 58 R49.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and profits for the years 2021, 2020 and 2019 were as follows:
(in millions)202120202019
Revenues:  
Bausch + Lomb$3,765 $3,415 $3,778 
Salix2,074 1,904 2,022 
International1,166 1,181 1,154 
Solta Medical308 253 194 
Diversified Products1,121 1,274 1,453 
Total revenues$8,434 $8,027 $8,601 
Segment profit:   
Bausch + Lomb$958 $909 $1,117 
Salix1,493 1,338 1,349 
International403 386 352 
Solta Medical167 131 84 
Diversified Products722 814 933 
Total3,743 3,578 3,835 
Corporate(792)(619)(609)
Amortization of intangible assets(1,375)(1,645)(1,897)
Goodwill impairments(469)— — 
Asset impairments, including loss on assets held for sale(234)(114)(75)
Restructuring, integration, separation and IPO costs(50)(22)(31)
Other expense, net(373)(502)(1,426)
Operating income (loss)450 676 (203)
Interest income13 12 
Interest expense(1,426)(1,534)(1,612)
Loss on extinguishment of debt(62)(59)(42)
Foreign exchange and other(30)
Loss before benefit from income taxes$(1,024)$(934)$(1,837)
Schedule of capital expenditures, depreciation and amortization by segment
Capital expenditures by segment for the years 2021, 2020 and 2019 were as follows:
(in millions)202120202019
Capital expenditures:   
Bausch + Lomb$201 $253 $186 
Salix
International22 29 39 
Solta Medical
Diversified Products
227 289 230 
Corporate42 13 40 
Total capital expenditures$269 $302 $270 
Schedule of revenues by segment and by product category Revenues by segment and product category were as follows:
Bausch + LombSalixInternationalSolta MedicalDiversified ProductsTotal
(in millions)For the year ended December 31, 2021
Pharmaceuticals$514 $2,066 $259 $— $923 $3,762 
Devices1,596 — — 308 — 1,904 
OTC1,388 — 136 — 1,532 
Branded and Other Generics 240 — 737 — 167 1,144 
Other revenues27 34 — 23 92 
$3,765 $2,074 $1,166 $308 $1,121 $8,434 
Bausch + LombSalixInternationalSolta MedicalDiversified ProductsTotal
For the year ended December 31, 2020
Pharmaceuticals$506 $1,899 $255 $— $1,020 $3,680 
Devices1,313 — — 253 — 1,566 
OTC1,311 — 112 — 1,430 
Branded and Other Generics 254 — 775 — 219 1,248 
Other revenues31 39 — 28 103 
$3,415 $1,904 $1,181 $253 $1,274 $8,027 
Bausch + LombSalixInternationalSolta MedicalDiversified ProductsTotal
For the year ended December 31, 2019
Pharmaceuticals$623 $2,022 $268 $— $1,165 $4,078 
Devices1,524 — — 194 — 1,718 
OTC1,322 — 119 — 1,447 
Branded and Other Generics 260 — 730 — 256 1,246 
Other revenues49 — 37 — 26 112 
$3,778 $2,022 $1,154 $194 $1,453 $8,601 
Schedule of revenues by geographic region
Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as follows:
(in millions)202120202019
U.S. and Puerto Rico$4,887 $4,791 $5,164 
China490 341 368 
Canada343 331 339 
Poland280 238 231 
Mexico256 225 228 
Japan230 226 241 
France208 179 201 
Russia160 137 180 
Egypt156 243 218 
Germany154 144 150 
United Kingdom116 86 115 
Spain88 78 86 
Italy80 71 85 
Other986 937 995 
$8,434 $8,027 $8,601 
Schedule of long-lived assets by geographic region
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2021 and 2020 were as follows:
(in millions)20212020
U.S. and Puerto Rico$743 $725 
Ireland336 328 
Canada123 110 
Poland75 83 
Germany87 80 
Mexico45 49 
France39 34 
China30 31 
Serbia25 30 
Italy 21 23 
Other 74 74 
$1,598 $1,567 
Schedule of external customers that accounted for 10% or more of total revenues
Customers that accounted for 10% or more of total revenues were as follows:
202120202019
AmerisourceBergen Corporation18%17%16%
McKesson Corporation16%17%17%
Cardinal Health, Inc.12%13%14%